Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...
Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
In a new study, researchers identify biomarkers that may predict the efficacy of low-dose IL-2 (Ld-IL2) treatment in people with systemic lupus erythematosus (SLE). IL-2 stands for interleukin-2 – a ...
Some patients with SLE and low-grade proteinuria may have early active lupus nephritis. Current systemic lupus erythematosus (SLE) guidelines recommend performing a kidney biopsy in patients with a ...
Objective To characterise the age-related impact of organ damage patterns on health-related quality of life (HRQoL) in ...
Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...
Certain autoantibodies were significantly associated with neuropsychiatric manifestations of systemic lupus erythematosus, emphasizing their utility for accurately diagnosing and managing this complex ...
New research identifies age, anti-β2GP1 antibodies, and low complement C3 as key risk factors for cerebral small vessel ...
In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback